The Herceptin Adjuvant (HERA) Trial Study Team demonstrated that the risk of local recurrence requiring radiotherapy did not increase in early-stage HER2-positive lobular breast cancer patients treated with trastuzumab (Piccart-Gebhart et al., 2005; Tolaney et al., 2015). Here, ERBB2 is linked to Hereditary breast cancer.